| 臺大學術典藏 |
2021-05-31T07:54:14Z |
GEF-H1 controls focal adhesion signaling that regulates mesenchymal stem cell lineage commitment
|
Huang I.-H.; Hsiao C.-T.; Wu J.-C.; Shen R.-F.; Liu C.-Y.; Wang Y.-K.; Chen Y.-C.; Huang C.-M.; del ?lamo J.C.; ZEE-FEN CHANG; Tang M.-J.; Khoo K.-H.; Kuo J.-C. |
| 臺大學術典藏 |
2018-09-10T14:54:22Z |
GEF-H1 controls microtubule-dependent sensing of nucleic acids for antiviral host defenses
|
Chiang, H.-S.;Zhao, Y.;Song, J.-H.;Liu, S.;Wang, N.;Terhorst, C.;Sharpe, A.H.;Basavappa, M.;Jeffrey, K.L.;Reinecker, H.-C.; Chiang, H.-S.; Zhao, Y.; Song, J.-H.; Liu, S.; Wang, N.; Terhorst, C.; Sharpe, A.H.; Basavappa, M.; Jeffrey, K.L.; Reinecker, H.-C.; Hao-Sen Chiang |
| 國立臺灣大學 |
2008 |
Gef-H1 Couples Nocodazole-Induced Microtubule Disassembly to Cell Contractility Via Rhoa
|
張元貞; 張智芬; CHANG, YUAN-CHEN; CHANG, ZEE-FEN |
| 國立臺灣大學 |
2008-05 |
GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA.
|
Chang, YC; Nalbant, P; Birkenfeld, J; Chang, ZF; Bokoch, GM. |
| 慈濟大學 |
2007 |
GEF-H1於乳癌轉移腫瘤細胞中受PTTG1/hSecurin的調控機制
|
廖苡竹 |
| 國立臺灣大學 |
2008 |
GEF-H1調控RhoA訊息傳遞對細胞命運決定及移動力之探討
|
張元貞; Chang, Yuan-Chen |
| 國立成功大學 |
2006-10 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Chang, Alex; Parikh, Purvish; Thongprasert, Sumitra; Tan, Eng Huat; Perng, Reury- Perng; Ganzon, Domingo; Yang, Chih-Hsin; Tsao, Chao-Jung; Watkins, Claire; Botwood, Nick; Thatcher, Nick |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 亞洲大學 |
2019-11 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo
|
La, Kuang-Chi;Lai, Kuang-Chi;闕甫伈;Chueh, Fu-Shin;Hs, Yung-Ting;Hsiao, Yung-Ting;Che, Zheng-Yu;Cheng, Zheng-Yu;Jin-Cherng, L;Lien, Jin-Cherng;Li, Kuo-Ching;Liu, Kuo-Ching;Peng, Shu-Fen;Peng, Shu-Fen;鍾景光 |
| 亞洲大學 |
2019-11 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
|
KC, Lai;KC, Lai;闕甫伈;FS, Chueh;YT, Hsiao;YT, Hsiao;ZY, Cheng;ZY, Cheng;JC, Lien;JC, Lien;KC, Liu;KC, Liu;SF, Peng;SF, Peng;JG, Chung;JG, Chung |
| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis
|
陳偉峻(Wei-Chun chen); 陳煒(Wei- Chen); 曾冠欽(Guan-Chin Teseng); 賴學洲(Hsueh-Chou Lai); 施純明(Chuen-Ming Shih); 夏德椿(Te-Chun Hsia) |
| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
|
陳偉峻(Wei-Chun chen);陳煒(Wei- Chen);曾冠欽(Guan-Chin Teseng);賴學洲(Hsueh-Chou Lai);施純明(Chuen-Ming Shih);夏德椿(Te-Chun Hsia) |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 國立臺灣大學 |
2009 |
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
|
楊志新; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2018-09-10T18:05:30Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang, C.-H. and Lee, C.-H. and Wang, J.-Y.; JANN-YUAN WANG; CHIA-HAO CHANG |
| 臺大學術典藏 |
2020-08-13T05:24:06Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang C.-H.;Lee C.-H.;Jann-Yuan Wang; Chang C.-H.; Lee C.-H.; JANN-YUAN WANG |
| 臺大學術典藏 |
2018-09-10T18:01:48Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: A cohort study in Taiwan
|
Chang, C.-H. and Lee, C.-H. and Ko, J.-C. and Chang, L.-Y. and Lee, M.-C. and Wang, J.-Y. and Yu, C.-J.; Chong-Jen Yu; JANN-YUAN WANG; CHIA-HAO CHANG; JEN-CHUNG KO; LIH-YU CHANG |
| 臺大學術典藏 |
2022-06-14T03:22:08Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan
|
LIH-YU CHANG |
| 臺大學術典藏 |
2017 |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Yu C.-J.; Lee M.-C.; JANN-YUAN WANG; Chang L.-Y.; Ko J.-C.; Lee C.-H.; Chang C.-H. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:20Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Wang J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Chih-Hsin Lee; JEN-CHANG KO; LIH-YU CHANG; Ming-Chia Lee; Jann-Yuan Wang; Chong-Jen Yu |
| 臺大學術典藏 |
2021-10-04T07:15:43Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T07:58:30Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:09Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
YU-YUN SHAO; Lin C.C.; Yang C.H. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y; Chia-Chi Lin; Yang C.H. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 國立臺灣大學 |
2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K.; 楊志新 |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 國家衛生研究院 |
2005-08-01 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Yang, CH; Huang, CJ; Yang, CS; Chu, YC; Cheng, AL; Whang-Peng, J; Yang, PC |
| 國立臺灣大學 |
2005 |
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing Atp-Binding Cassette Family Protein
|
楊志新; 黃靜如; 楊朝順; 朱玉娟; 鄭安理; 彭汪嘉康; 楊泮池; YANG, CHIH-HSIN; HUANG, CHING-JU; YANG, CHAO-SHUN; CHU, YU-CHUAN; CHENG, ANN-LII; WHANG-PENG, JACQUELINE; YANG, PAN-CHYR |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Chih-Hsin Yang;Huang C.-J;Yang C.-S;Chu Y.-C;Cheng A.-L;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Huang C.-J; Yang C.-S; Chu Y.-C; Cheng A.-L; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-12-02T02:35:41Z |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Yang C.-H.;Huang C.-J.;Yang C.-S.;Chu Y.-C.;Cheng A.-L.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Huang C.-J.; Yang C.-S.; Chu Y.-C.; Cheng A.-L.; Whang-Peng J.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-09-01T02:02:17Z |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
|
Yang C.-H.; Huang C.-J.; Yang C.-S.; Chu Y.-C.; ANN-LII CHENG; Whang-Peng J.; Yang P.-C. |
| 臺大學術典藏 |
2018-09-10T08:28:52Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu, J.-Y. and Shih, J.-Y. and Chen, K.-Y. and Yang, C.-H. and Yu, C.-J. and Yang, P.-C.; Chong-Jen Yu; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-05-26T09:27:12Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y;Shih J.-Y;Chen K.-Y;Chih-Hsin Yang;Yu C.-J;Yang P.-C.; Wu J.-Y; Shih J.-Y; Chen K.-Y; CHIH-HSIN YANG; Yu C.-J; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:23Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Yang P.-C.; Wu J.-Y.;Shih J.-Y.;Chen K.-Y.;Yang C.-H.;Chong-Jen Yu;Yang P.-C.; Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-13T06:33:53Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Wu J.-Y.;Jin-Yuan Shih;Chen K.-Y.;Yang C.-H.;Yu C.-J.;Yang P.-C.; Yang P.-C.; JIN-YUAN SHIH; Chen K.-Y.; Yang C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-12-02T02:34:10Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; Yu C.-J.; Pan-Chyr Yang; Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; Yu C.-J.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-04-29T02:38:41Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Anonymous |
| 臺大學術典藏 |
2021-04-29T05:09:12Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; KUAN-YU CHEN; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:36Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; CHONG-JEN YU; Yang P.-C. |
